Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients

J Eur Acad Dermatol Venereol. 2022 Oct;36(10):e838-e841. doi: 10.1111/jdv.18314. Epub 2022 Jun 22.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal*
  • Humans
  • Psoriasis* / drug therapy

Substances

  • Antibodies, Monoclonal
  • risankizumab